Search

Marco A Biamonte

age ~54

from San Diego, CA

Also known as:
  • Marco Biamonte
  • Marko Martinborough
Phone and address:
5350 Toscana Way, San Diego, CA 92122
8586422084

Marco Biamonte Phones & Addresses

  • 5350 Toscana Way, San Diego, CA 92122 • 8586422084
  • 5220 Fiore Ter, San Diego, CA 92122 • 8586422084

Us Patents

  • Pyrazolopyrimidines And Related Analogs As Hsp90-Inhibitors

    view source
  • US Patent:
    7148228, Dec 12, 2006
  • Filed:
    Sep 20, 2004
  • Appl. No.:
    10/946637
  • Inventors:
    Srinivas Rao Kasibhatla - San Diego CA, US
    Marco A. Biamonte - San Diego CA, US
    Kevin D. Hong - San Diego CA, US
    David Hurst - San Diego CA, US
    Marcus F. Boehm - San Diego CA, US
  • Assignee:
    Conforma Therapeutics Corporation - San Diego CA
  • International Classification:
    C07D 487/04
    A61K 31/519
    A61P 35/00
    A61P 37/06
    A61P 29/00
  • US Classification:
    5142621, 544262
  • Abstract:
    A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof:.
  • Purine Analogs Having Hsp90-Inhibiting Activity

    view source
  • US Patent:
    7241890, Jul 10, 2007
  • Filed:
    Oct 30, 2002
  • Appl. No.:
    10/494414
  • Inventors:
    Srinivas Rao Kasibhatla - San Diego CA, US
    Kevin Hong - San Diego CA, US
    Lin Zhang - San Diego CA, US
    Marco Antonio Biamonte - San Diego CA, US
    Marcus F. Boehm - San Diego CA, US
    Jiandong Shi - San Diego CA, US
    Junhua Fan - San Diego CA, US
  • Assignee:
    Conforma Therapeutics Corporation - San Diego CA
  • International Classification:
    C07D 473/40
    C07D 473/24
    C07D 473/34
    A61K 31/52
    A61P 35/00
  • US Classification:
    544276, 544265, 544277
  • Abstract:
    Novel purine compounds of Formula I.
  • Pharmaceutically Active Benzsulfonamide Derivatives As Inhibitors Of Protein Junkinases

    view source
  • US Patent:
    7417058, Aug 26, 2008
  • Filed:
    Sep 27, 2001
  • Appl. No.:
    10/381197
  • Inventors:
    Serge Halazy - Vetraz-Monthoux, FR
    Dennis Church - Commugny, CH
    Stephen J. Arkinstall - Belmont MA, US
    Marco Biamonte - San Diego CA, US
    Montserrat Camps - Versoix, CH
    Jean-Pierre Gotteland - Beaumont, FR
    Thomas Rueckle - Plan-les-Ouates, CH
  • Assignee:
    Laboratoires Serono S.A. - Coinsins
  • International Classification:
    A61K 31/445
    A61P 25/00
    A61P 37/00
    C07D 211/96
  • US Classification:
    514322, 514323, 514326, 546199, 546201, 546212
  • Abstract:
    The present invention is related to benzsulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzsulfonamide derivatives. Said benzsulfonamide derivatives are ef-ficient modulators of the JNK pathway, they are in particular efficient and selective in-hibitors of JNK 2 and 3. The present invention is furthermore related to novel benzsul-fonamide derivatives as well as to methods of their preparation (I). The compounds of formula I according to the present invention being suitable pharma-ceutical agents are those wherein Ar1 is a substituted or unsubstituted aryl or heteroaryl group. X is O or S, preferably O. R1 is hydrogen or a C1-C6-alkyl group, preferably H. R2 is hydrogen, —COOR3, —CONR3R3′, OH, a C1-C4 alkyl substituted with an OH group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt; n is either 0 or 1, preferably 1.
  • Pharmaceutically Active Sulfonyl Hydrazide Derivatives

    view source
  • US Patent:
    7432286, Oct 7, 2008
  • Filed:
    Sep 28, 2000
  • Appl. No.:
    10/088074
  • Inventors:
    Stephen Arkinstall - Belmont MA, US
    Serge Halazy - Vetraz-Monthoux, FR
    Dennis Church - Commugny, CH
    Montserrat Camps - Versoix, CH
    Thomas Rueckle - Plan-les-Ouates, CH
    Jean-Pierre Gotteland - Beaumont, FR
    Marco Biamonte - San Diego CA, US
  • Assignee:
    Laboratories Serono SA - Vaud
  • International Classification:
    C07D 417/12
    C07D 213/74
    A61K 31/44
  • US Classification:
    514336, 514614, 5462681, 564 81
  • Abstract:
    The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation. In Formula (I) Arand Arare independently from each other an unsubstituted or substituted aryl or beteroaryl group, Xand Xare independently from each other O or S; R, R, Rare independently from each other hydrogen or a C-C-alkyl substituent or Rforms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar; or Rand Rform a substituted or unsubstituted 5-6-membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubstituted or substituted 4-8 membered heterocycle containing at least one heteroatom, or G is a substituted or unstibstituted C-C-alkyl group.
  • Alkynyl Pyrrolo[2,3-D]Pyrimidines And Related Analogs As Hsp90-Inhibitors

    view source
  • US Patent:
    7544672, Jun 9, 2009
  • Filed:
    Mar 29, 2006
  • Appl. No.:
    11/277918
  • Inventors:
    Srinivas Rao Kasibhatla - San Diego CA, US
    Marco Antonio Biamonte - San Diego CA, US
    Jiandong Shi - San Diego CA, US
    Marcus F. Boehm - San Diego CA, US
  • Assignee:
    Conforma Therapeutics Corporation - San Diego CA
  • International Classification:
    C07D 487/04
    C07F 9/38
    A61K 31/519
    A61K 31/662
  • US Classification:
    514 81, 5142651, 544243, 544280
  • Abstract:
    Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
  • Pharmaceutically Active Sulfonamide Derivatives Bearing Both Lipophilic And Ionisable Moieties As Inhibitors Of Protein Junkinases

    view source
  • US Patent:
    7544700, Jun 9, 2009
  • Filed:
    Sep 27, 2001
  • Appl. No.:
    10/381665
  • Inventors:
    Serge Halazy - Vetraz-Monthoux, FR
    Dennis Church - Commugny, CH
    Stephen J. Arkinstall - Belmont MA, US
    Marco Biamonte - San Diego CA, US
    Montserrat Camps - Versoix, CH
    Jean-Pierre Gotteland - Beaumont, FR
    Thomas Rueckle - Plan-les-Ouates, CH
  • Assignee:
    Laboratoires Serono SA - Coinsins
  • International Classification:
    A61P 25/00
    A61P 25/16
    A61K 31/4535
    A61K 31/55
    A61K 31/4025
    C07D 333/34
    C07D 409/12
    C07D 409/14
    C07D 413/14
  • US Classification:
    514322, 514323, 514326, 546199, 546201, 546212
  • Abstract:
    The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C1-C6-alkyl group, or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula (I) is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionizable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide.
  • Pharmaceutically Active Sulfonyl Amino Acid Derivatives

    view source
  • US Patent:
    7638538, Dec 29, 2009
  • Filed:
    Sep 28, 2000
  • Appl. No.:
    10/088090
  • Inventors:
    Stephen Arkinstall - Belmont MA, US
    Serge Halazy - Vetraz-Monthoux, FR
    Dennis Church - Commugny, CH
    Montserrat Camps - Versoix, CH
    Thomas Rueckle - Plan-les-Ouates, CH
    Jean-Pierre Gotteland - Beaumont, FR
    Marco Biamonte - San Diego CA, US
  • Assignee:
    Laboratoires Serono S.A. - Coinsins
  • International Classification:
    A61K 31/44
    C07D 409/12
  • US Classification:
    514336, 5462804
  • Abstract:
    The present invention is related to sulfonyl amino acid derivatives of formula (I), notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl amino acid derivatives. Said sulfonyl amino acid are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 33. The present invention is furthermore related to novel sulfonyl amino acid derivatives as well as to methods of their preparation.
  • Arylsulfonamide Derivatives As C-Jun-N-Terminal Kinases (Jnk's) Inhibitors

    view source
  • US Patent:
    7683078, Mar 23, 2010
  • Filed:
    Jul 15, 2002
  • Appl. No.:
    10/484744
  • Inventors:
    Thomas Rueckle - Plan-les-Ouates, CH
    Jean-Pierre Gotteland - Beaumont, FR
    Russel J. Thomas - Boars Hill Oxford, GB
    Marco Biamonte - San Diego CA, US
  • Assignee:
    Laboratoires Serono S.A. - Coinsins
  • International Classification:
    C07D 411/12
    C07D 409/12
    C07D 333/32
    A61K 31/445
    A61K 31/44
    A61K 31/40
    A61K 31/38
  • US Classification:
    514326, 514342, 514422, 514446, 546213, 5462814, 548527, 549 65
  • Abstract:
    The present invention relates to sulfonamide derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are useful in the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases. Furthermore, said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and -3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. Formula (I) IAris a substituted or unsubstituted aryl or heteroaryl group; X is O or S, preferably O; Ara substituted or unsubstituted arylene or heteroarylene group; Rand Rare independently selected from the group consisting of hydrogen and a C-C-alkyl group.

Resumes

Marco Biamonte Photo 1

President, Founder

view source
Location:
Atlanta, GA
Industry:
Pharmaceuticals
Work:
Drug Discovery for Tropical Diseases since 2011
President, Founder

Biogen Idec 2006 - 2011
Senior Scientist (Medicinal Chemistry)

Conforma Therapeutics 2001 - 2006
Scientist

Serono Pharmaceuticals 1999 - 2001
Scientist
Education:
Eidgenössische Technische Hochschule Zürich 1995 - 1998
Post Doc, Organic chemistry
University of Cambridge 1991 - 1995
Ph.D., Organic Chemistry
Ecole polytechnique fédérale de Lausanne 1985 - 1990
Skills:
Drug Discovery
Medicinal Chemistry
Oncology
Drug Design
Biotechnology
Marco Biamonte Photo 2

Senior Scientist

view source
Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Conforma Therapeutics
Senior Scientist
Marco Biamonte Photo 3

Fse Mvs Field Cs Support

view source
Location:
San Diego, CA
Industry:
Medical Devices
Work:
Biosteril Italia S.r.l
Informatore Scientifico

Bios Healthcare Srl Nov 2016 - Feb 2017
Tecnico Commerciale Specialista Di Prodotto

Astra Srl Mar 2016 - Oct 2016
Ingegnere Biomedico

Istituto Di Bioimmagini E Fisiologia Molecolare Ibfm Del Cnr Nov 2015 - Mar 2016
Ingegnere Biomedico

Philips Nov 2015 - Mar 2016
Fse Mvs Field Cs Support
Name / Title
Company / Classification
Phones & Addresses
Marco A. Biamonte
President
Drug Discovery for Tropical Diseases
Commercial Physical Research
10835 Rd To The Cure, San Diego, CA 92121
11128 Portobelo Dr, San Diego, CA 92124

Googleplus

Marco Biamonte Photo 4

Marco Biamonte


Get Report for Marco A Biamonte from San Diego, CA, age ~54
Control profile